Dare Bioscience Inc.
05/18/2026 | Press release | Distributed by Public on 05/18/2026 14:26
Private Placement (Form 8-K)
| Item 3.02 | Unregistered Sales of Equity Securities. |
Daré Bioscience, Inc. ("Daré" "we," "us," or "our") completed closings of its previously announced Regulation A offering of up to 4,854,000 units (each, an "Investor Unit" and collectively the "Investor Units"), each consisting of one share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") and two warrants, each to purchase one share of our common stock ("Investor Warrants"), with each Investor Unit being offered at an offering price of $5.00 (the "Offering"). The closings occurred on May 14, 2026. In connection therewith, we issued an aggregate of 50,000 Investor Units consisting of 50,000 shares of Series A Preferred Stock and Investor Warrants to purchase up to 100,000 shares of our common stock.
The offering of the Investor Units is being conducted pursuant to our offering statement on Form 1-A (File No. 024-12688), as amended, which was most recently qualified by the U.S. Securities and Exchange Commission (the "SEC") on April 1, 2026, and the offering circular dated January 6, 2026, and the offering circular supplements dated March 26, 2026, and May 14, 2026, which form a part thereof. Additional information regarding the Offering and the terms of conversion and exercise of the Series A Preferred Stock and Investor warrants was previously reported in our Current Report on Form 8-K filed with the SEC on January 29, 2026, and is incorporated herein by reference.
Dare Bioscience Inc. published this content on May 18, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 18, 2026 at 20:26 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]